Laboratory Immunological Microenvironment and Tumors, INSERM U872, Cordeliers Research Centre, Paris, France.
Cancer Res. 2011 Oct 15;71(20):6391-9. doi: 10.1158/0008-5472.CAN-11-0952. Epub 2011 Sep 7.
De novo formation of tertiary lymphoid structures (TLS) has been described in lung cancers. Intratumoral TLS seem to be functional and are associated with a long-term survival for lung cancer patients, suggesting that they represent an activation site for tumor-specific T cells. Here, we characterized T-cell recruitment to TLS in human lung cancer to identify the adhesion molecules and chemoattractants orchestrating this migration. We found that most TLS T cells were CD62L+ and mainly of CD4+ memory phenotype, but naive T cells were highly enriched in these structures as compared with the rest of the tumor. A specific gene expression signature associated with T cell presence was identified in TLS, which included chemokines (CCL19, CCL21, CXCL13, CCL17, CCL22, and IL16), adhesion molecules (ICAM-2, ICAM-3, VCAM-1, and MAdCAM-1) and integrins (alphaL, alpha4, and alphaD). The presence of the corresponding receptors on TLS T cells was confirmed. Intratumoral PNAd+ high endothelial venules also were exclusively associated with TLS and colocalized with CD62L+ lymphocytes. Together, these data bring new insights into the T-cell recruitment to intratumoral TLS and suggest that blood T cell enter into TLS via high endothelial venules, which represent a new gateway for T cells to the tumor. Findings identify the molecules that mediate migration of tumor-specific T cells into TLS where T cell priming occurs, suggesting new strategies to enhance the efficacy of cancer immunotherapies.
在肺癌中已经描述了三级淋巴结构(TLS)的从头形成。肿瘤内 TLS 似乎具有功能,并与肺癌患者的长期生存相关,这表明它们代表了肿瘤特异性 T 细胞的激活部位。在这里,我们描述了人类肺癌中 T 细胞向 TLS 的募集,以鉴定协调这种迁移的粘附分子和趋化因子。我们发现,大多数 TLS T 细胞是 CD62L+,主要是 CD4+记忆表型,但与肿瘤的其余部分相比,这些结构中幼稚 T 细胞高度富集。在 TLS 中鉴定出与 T 细胞存在相关的特定基因表达特征,其中包括趋化因子(CCL19、CCL21、CXCL13、CCL17、CCL22 和 IL16)、粘附分子(ICAM-2、ICAM-3、VCAM-1 和 MAdCAM-1)和整合素(alphaL、alpha4 和 alphaD)。在 TLS T 细胞上也确认了相应受体的存在。肿瘤内 PNAd+高内皮小静脉也仅与 TLS 相关,并与 CD62L+淋巴细胞共定位。这些数据为肿瘤内 TLS 中 T 细胞的募集提供了新的见解,并表明血液 T 细胞通过高内皮小静脉进入 TLS,这为 T 细胞进入肿瘤提供了一个新的途径。研究结果确定了介导肿瘤特异性 T 细胞进入发生 T 细胞启动的 TLS 的迁移的分子,这表明了增强癌症免疫疗法效果的新策略。